DCGI has recently granted permission for the manufacturing and marketing of “Cefepime+Enmetazobactam” – for a NCE manufactured by Orchid Pharma.
The use case of this drug is similar to that of WCK 5222. “treatment of complicated Urinary Tract Infections (cUTI) including acute Pyelonephritis, HospitalAcquired Pneumonia (HAP) including Ventilator-associated pneumonia (VAP), and Bacteremia when it is associated or suspected to be associated with either complicated urinary tract
infections or hospital-acquired pneumonia”
Cefepime+Zidebactam was found out to be more potent than Cefepime+Enmetazobactam as per Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Enterobacterales – PMC)
How would this affect the market for WCK 5222? Will a competitor launching a similar product earlt (albeit less potent/efficient) change the pricing strategy of Wockhardt? What if this product gains distribution before WCK 5222 is released? Would love to know your thoughts on this. Disc: Invested
Thanks
Subscribe To Our Free Newsletter |